In NSCLC patients with EGFR mutations (exon 19 deletion or L858R allele), the clinical practice guidelines of the 2022 National Comprehensive Cancer Network (NCCN) give priority to osimertinib (Ettinger et al., 2022). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.